Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of “Hold” from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $6.20.

Several equities analysts recently weighed in on STTK shares. Citigroup lifted their target price on shares of Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Monday, December 1st. Finally, Piper Sandler started coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company.

Shattuck Labs Trading Up 5.3%

Shares of STTK opened at $3.97 on Thursday. The stock’s fifty day simple moving average is $3.72 and its 200 day simple moving average is $2.40. The firm has a market capitalization of $251.22 million, a P/E ratio of -3.89 and a beta of 1.52. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $4.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in STTK. Orbimed Advisors LLC acquired a new stake in Shattuck Labs in the 3rd quarter valued at about $15,072,000. Pinnacle Associates Ltd. raised its position in Shattuck Labs by 1.8% during the third quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock valued at $3,319,000 after buying an additional 25,000 shares during the period. Bank of America Corp DE lifted its position in shares of Shattuck Labs by 2,968.2% in the third quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock worth $2,705,000 after purchasing an additional 1,094,997 shares in the last quarter. 683 Capital Management LLC boosted its stake in shares of Shattuck Labs by 4.3% during the 2nd quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock valued at $867,000 after buying an additional 45,000 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Shattuck Labs by 32.1% in the fourth quarter. Geode Capital Management LLC now owns 618,277 shares of the company’s stock worth $2,258,000 after buying an additional 150,318 shares during the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.